Korio offers a randomization and trial supply management (RTSM) platform designed to improve clinical trial quality, speed, and reliability. The platform enables users to adapt to protocol changes, surface audit trails and cross-portfolio data, and flag integration disruptions. When customers need guidance, Korio provides access to knowledgeable and responsive RTSM experts. Led by CEO Ryan Keane and based in Doylestown, PA, the company emphasizes expert client services and support. Korio intends to use the Series A proceeds to accelerate global expansion with a focus on its client services and support team. Financial terms of the round were not disclosed; the round was led by BIP Ventures with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners, and other strategic investors. Korio offers a clinical trial software platform focused on Randomization & Trial Supply Management (RTSM) that streamlines processes and delivers predictable outcomes within shorter timeframes. The platform integrates insights and expertise from industry subject‑matter experts to challenge complex, manual workflows common among RTSM providers. Led by CEO Ryan Keane, the company emphasizes a technology‑first approach to replace manual processes. Korio intends to use its recent funding to support expansion and to bolster its team. The company said the capital will help it respond to increasing demand from life sciences and clinical research organizations. The articles do not disclose additional operating metrics or past financing details.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2023